Our expertise

illustration médecine

Precision medicine

The emergence of artificial intelligence, (AI), applied to the healthcare sector has seen medicine evolve towards medicine of the 4Ps: Preventive, Predictive, Participative, and Personalized. This new approach has emerged on the basis of a simple premise: the same drug with the same posology isn’t suitable for everyone.

Taking into account the individual variability of genes, the environment, and the way of life of each individual, personalized medicine offers the potential for significant improvement in each patient’s treatment journey. The use of artificial intelligence, (AI), in the healthcare sector now enables us to provide values for and to learn about the efficacy of a treatment, depending on the individual and their biological characteristics.

In-Vitro Diagnostic Medical Devices

mYXpression’s innovations are based on a diagnostic method known as “in vitro analysis”. This technique involves the use of specialized equipment for the in-depth examination of blood samples. The aim is to sequence the patient’s messenger RNA in order to detect and analyze specific biological indicators. This targeted, individualized approach facilitates understanding of each patient’s specific needs, contributing to the formulation of tailor-made therapeutic recommendations.

In Silico Technology

The solutions developed by mYXpression are based on a technology known as In Silico. This approach uses powerful computers to model various phenomena, including the behavior of molecules in the patient’s body. Thanks to these numerical simulations, it is now possible to assess the potential efficacy of a biotherapy for a given patient, thus establishing a personalized score.

Artificial intelligence

The core of our business
Prediction of extremely highly complex phenomena (Megadata / AI) 10 years of R&D
Why are predictions valuable?
You can learn information through observation in order to anticipate phenomena
How are the predictions made?
Algorithmic segmentation and a database of profiles to prevent the theoretical reading that would require infinite quantities of data

The three technological
pillars of innovation

A profiles database of therapeutic efficacy

Made up of more than 20 million profiles, the database is constantly being updated to collect the maximum amount of information about individual responses to biotherapies.

A messenger RNA signature of the therapeutic response via NGS technology (1)

mYXpression messenger RNA sequence for patients through next-generation technology known as high-throughput NGS, which enables DNA and RNA to be sequenced very rapidly, providing valuable information to answer almost any biological question.

A therapeutic efficacy score for each biotherapy

The algorithms calculate the Therapeutic Efficacy Scores for each of the 6 main biotherapies on the market(2) using both the efficacy profile database and the messenger RNA signature.

(1) Next-Generation Sequencing
(2) 85% of prescriptions

The largest data sets on autoimmune and inflammatory diseases

Several years ago, mYXpression patiently built up the most complete integrated transcriptomic data sets of autoimmune and inflammatory diseases.

Data about rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, lupus, Crohn’s disease, and hemorrhagic colitis have been collected continuously. The approach used by our technology of studying the interaction between a molecule and the biology of the patient is also relevant for rare diseases, such as Sjögren’s syndrome, Behçet’s disease, hidradenitis suppurativa, Graves’ disease, and Kawasaki disease.

The data come from various sources and are harmonized using our Data Processing Curative Model, enabling an automatic and generalizable learning environment to be obtained that can be used to create predictive models and analyses adapted to your needs.

How are the data converted into information with a high added value?

After identifying the most relevant studies in the field of autoimmune disease and biopharmaceuticals, the raw data these studies contained were extracted and then stored in order to be converted into information with a high added value.

From this knowledge, a unique information database was born, composed of elements of patients’ own immune dysregulation to immune diseases and supplemented with information specific to each of the existing biopharmaceuticals.